Literature DB >> 8489671

Respiratory failure following adenosine administration.

K K Burkhart1.   

Abstract

Adenosine is frequently administered to convert the rhythm of patients with paroxysmal supraventricular tachycardia to sinus rhythm. Adverse reactions are common after its administration, but these have been short-lived because adenosine has a half-life of less than 10 seconds. This report describes a 54-year-old male patient with chronic obstructive pulmonary disease who presented with paroxysmal supraventricular tachycardia at 200 beats/min. A 12-mg bolus injection of adenosine aggravated mild bronchospasm and produced respiratory failure. The patient subsequently required ventilatory support for 9 days. The presence of bronchoconstriction should be considered as a possible contraindication to the administration of intravenous adenosine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489671     DOI: 10.1016/0735-6757(93)90138-2

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  4 in total

1.  Respiratory arrest during dipyridamole stress testing.

Authors:  G S Hillis; A al-Mohammad; K P Jennings
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

2.  Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.

Authors:  Carlos Salgado Garcia; Carlos Salgado Garcia; Amelia Jimenez Heffernan; Amelia Jimenez Heffernan; Elena Sanchez de Mora; Carlos Ramos Font; Juana Lopez Martin; Francisco Rivera de los Santos; Ignacio Ynfante Milá
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-16       Impact factor: 9.236

3.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

4.  Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

Authors:  Gregory S Thomas; Bruce R Tammelin; George L Schiffman; Rudy Marquez; Deborah L Rice; Douglas Milikien; Vandana Mathur
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.